Evaluation of the in vitro activity of amphotericin B by time–kill curve methodology against large and small capsulate C. neoformans isolates
Abstract
We have evaluated and compared the activity of amphotericin B (AMB) by time-kill curve methodology against 20 clinical Cryptococcus neoformans isolates in which capsule induction in vitro was performed. Overall, large capsulated isolates were more resistant to killing by AMB over time when compared with those small capsulate ones.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
C. neoformans cells with thicker capsules exhibit amphotericin B resistance and enhanced virulence.
“C. neoformans cells with thicker capsules exhibit amphotericin B resistance and enhanced virulence40,41”
From Treatment strategies for cryptococcal infection: challenges, advances and future outlook (2021) · cites this paper as [40]
Cites
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660 · see citing works
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial
Brouwer, A. E., Rajanuwong, A., Chierakul, W., Griffin, G. E., Larsen, R. A., White, N. J., & Harrison, T. S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16301-0 · Cited by 466 · see citing works
Pfaller, M. A., Sheehan, D. J., & Rex, J. H. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.268-280.2004 · Cited by 352 · see citing works
Zaragoza, Ó., Chrisman, C. J., Castelli, M. V., Frasés, S., Cuenca‐Estrella, M., Rodrı́guez-Tudela, J. L., & Casadevall, A. (2008) · Cellular Microbiology · doi:10.1111/j.1462-5822.2008.01186.x · Cited by 252 · see citing works
A Yeast under Cover: the Capsule ofCryptococcus neoformans
Bose, I., Reese, A. J., Ory, J. J., Janbon, G., & Doering, T. L. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.4.655-663.2003 · Cited by 231 · see citing works
Singh, N., Dromer, F., Perfect, J. R., & Lortholary, O. (2008) · Clinical Infectious Diseases · doi:10.1086/592690 · Cited by 220 · see citing works
Nussbaum, J. C., Jackson, A., Namarika, D., Phulusa, J., Kenala, J., Kanyemba, C., Jarvis, J. N., Jaffar, S. S., Hosseinipour, M. C., Kamwendo, D., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/649861 · Cited by 192 · see citing works
Ernst, E. J., Klepser, M. E., & Pfaller, M. A. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1108-1111.2000 · Cited by 181 · see citing works
Induction of Capsule Growth inCryptococcus neoformansby Mammalian Serum and CO2
Zaragoza, Ó., Fries, B. C., & Casadevall, A. (2003) · Infection and Immunity · doi:10.1128/iai.71.11.6155-6164.2003 · Cited by 175 · see citing works
Susceptibility testing of Cryptococcus neoformans: a microdilution technique
Ghannoum, M. A., Ibrahim, A. S., Fu, Y., Shafiq, M. C., Edwards, J. E., & Criddle, R. S. (1992) · Journal of Clinical Microbiology · doi:10.1128/jcm.30.11.2881-2886.1992 · Cited by 145 · see citing works
Capsule Structural Heterogeneity and Antigenic Variation in Cryptococcus neoformans
McFadden, D. C., Fries, B. C., Wang, F., et al. (2007) · Eukaryotic Cell · doi:10.1128/ec.00162-07 · Cited by 105 · see citing works
Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans
Moyrand, F., Klaproth, B., Himmelreich, U., Dromer, F., & Janbon, G. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03059.x · Cited by 100 · see citing works
Rodrı́guez-Tudela, J. L., Martín-Díez, F., Cuenca‐Estrella, M., Rodero, L., Carpintero, Y., & Gorgojo, B. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.400-404.2000 · Cited by 41 · see citing works
Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS
Rodero, L., Córdoba, S. B., Cahn, P. E., Soria, M., Lucarini, M., Davel, G., Kaufman, S. C., Canteros, C. E., & Guelfand, L. I. (2000) · Medical Mycology · doi:10.1080/mmy.38.3.201.207 · Cited by 37 · see citing works
Self-citationPappalardo, M. C. S. M., Szeszs, M. W., Martins, M. A., Bacetti, L. B., Bonfietti, L. X., Purisco, S. U., Baez, A. A., & Melhem, M. D. S. C. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.02.007 · Cited by 28 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Treatment strategies for cryptococcal infection: challenges, advances and future outlook
Iyer, K. R., Revie, N. M., Fu, C., Robbins, N., & Cowen, L. E. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00511-0 · Cited by 363 · see citing works
A titanic drug resistance threat in Cryptococcus neoformans
Zafar, H., Altamirano, S., Ballou, E. R., & Nielsen, K. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.11.001 · Cited by 76 · see citing works
- Authors
- Córdoba, S., Afeltra, J., & Vitale, R. G.
- Affiliations
- Administración Nacional de Laboratorios e Institutos de Salud (AR)
- Universidad de Buenos Aires (AR)
- Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
- Corresponding author
- Vitale, Roxana G.
- Venue
- Diagnostic Microbiology and Infectious Disease
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 71
- Issue
- 3
- Pages
- 260-262
- ISSN
- 0732-8893 (ISSN-L)
- OpenAlex
- W2048763561
- Cited by
- 17
- References
- 15
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 1 · 2015: 2 · 2014: 1
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diagnostic Microbiology and Infectious Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- amphotericin B, Cryptococcus neoformans, encapsulation, antifungal susceptibility, time-kill kinetics, in vitro antifungal activity, clinical isolates
- MeSH terms
- Amphotericin B, Antifungal Agents, Cryptococcus neoformans, Humans, Microbial Sensitivity Tests, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
